Literature DB >> 1423431

Reactive and reparative myocardial fibrosis in arterial hypertension in the rat.

C G Brilla1, K T Weber.   

Abstract

OBJECTIVE: Myocardial fibrosis is an important determinant of pathological hypertrophy. In two experimental models of arterial hypertension the purpose of the study was (a) to determine total collagen volume fraction and relative contribution of scarring and perivascular/interstitial fibrosis; and (b) to assess the effects of the aldosterone receptor antagonist spironolactone on these patterns of fibrosis.
METHODS: 76 eight week old Sprague-Dawley rats weighing 180 to 200 g were used for the studies. Using videodensitometry total collagen volume fraction was separated into the various components for the left and right ventricles in the following experimental models: renovascular hypertension occurring following unilateral renal ischaemia; continuous aldosterone administration via osmotic minipumps with either high (AL) or low (ALLO) sodium diet; renovascular hypertension and AL after pretreatment and continuous treatment with either 20 or 200 mg.kg-1.d-1 subcutaneously of the competitive aldosterone receptor antagonist spironolactone. All groups were compared to age and sex matched controls.
RESULTS: After eight weeks, systolic pressure was comparably increased in renovascular hypertension and AL and it remained raised with low dose spironolactone treatment in either model, but was normal with high dose spironolactone or low sodium diet. Left ventricular hypertrophy, expressed as a significant increase in left to right ventricular weight and left ventricle to body weight ratios, was present in renovascular hypertension, AL, and AL + low dose spironolactone compared to control (p < 0.005). In either ventricle: (1) the amount of interstitial/perivascular fibrosis and myocardial scarring was increased (p < 0.005) in renovascular hypertension and AL compared to control; (2) each was reduced (p < 0.005) with either dose of spironolactone; and (3) only scars were seen in ALLO.
CONCLUSIONS: Myocardial fibrosis of either ventricle was comparable in renovascular hypertension and AL. Spironolactone was able largely to prevent the perivascular/interstitial fibrosis and scarring in either model irrespective of the development of left ventricular hypertrophy and arterial hypertension. Low sodium diet in hyperaldosteronism prevented hypertension and left ventricular hypertrophy, but not scarring. These findings suggest that a rise in plasma aldosterone, relative to sodium intake, may play a role in mediating collagen accumulation in the heart during the development of experimental arterial hypertension.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423431     DOI: 10.1093/cvr/26.7.671

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  41 in total

Review 1.  Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease.

Authors:  Emmanuel L Bravo
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

Review 2.  Aldosterone blockade in cardiovascular disease.

Authors:  Allan D Struthers
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

3.  Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice.

Authors:  Sandra B Haudek; Ying Xia; Peter Huebener; John M Lee; Signe Carlson; Jeff R Crawford; Darrell Pilling; Richard H Gomer; JoAnn Trial; Nikolaos G Frangogiannis; Mark L Entman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-17       Impact factor: 11.205

Review 4.  Cardiac fibrosis: potential therapeutic targets.

Authors:  Shuin Park; Ngoc B Nguyen; Arash Pezhouman; Reza Ardehali
Journal:  Transl Res       Date:  2019-03-09       Impact factor: 7.012

Review 5.  Spironolactone in congestive heart failure.

Authors:  J E Soberman; K T Weber
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

Review 6.  Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles.

Authors:  Mohammed I Danjuma; Ipshita Mukherjee; Janine Makaronidis; Serge Osula
Journal:  Curr Hypertens Rep       Date:  2014-02       Impact factor: 5.369

Review 7.  Vascular remodeling and mineralocorticoids.

Authors:  K T Weber; Y Sun; S E Campbell; S H Slight; V K Ganjam
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

8.  Mineralocorticoid receptor antagonists attenuate exaggerated exercise pressor reflex responses in hypertensive rats.

Authors:  Ryan M Downey; Masaki Mizuno; Jere H Mitchell; Wanpen Vongpatanasin; Scott A Smith
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-07-21       Impact factor: 4.733

Review 9.  Diastolic heart failure in the elderly and the potential role of aldosterone antagonists.

Authors:  Ashwani Kumar; Gary Meyerrose; Vineeta Sood; Chanwit Roongsritong
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

10.  Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism.

Authors:  Jörg Peters; Torsten Schlüter; Thomas Riegel; Barbara S Peters; Andreas Beineke; Ulrike Maschke; Norbert Hosten; John J Mullins; Rainer Rettig
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-11       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.